Prosight Management, LP Compass Therapeutics, Inc. Transaction History

Prosight Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.87 - $3.25 $278,330 - $483,730	-148,840 Reduced 13.73%	935,157 $1.84 Million
Q2 2023 Aug 14, 2023	BUY	$2.64 - $3.48 $1.07 Million - $1.41 Million	405,697 Added 59.81%	1,083,997 $3.45 Million
Q1 2023 May 12, 2023	BUY	$3.14 - $5.48 $2.13 Million - $3.72 Million	678,300 New	678,300 $2.22 Million

92M

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $161M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.